Munich, Planegg (Germany), June 4, 2025 – leon-nanodrugs GmbH (LEON), a German Pharmatech company, is pleased to announce the appointment of Dr. Wolfgang Hofmann as its new Chief Executive Officer (CEO), effective immediately. With his extensive experience in scaling life science ventures and leading international teams, Dr. Hofmann will guide LEON through its next phase of growth. Under his leadership, LEON will focus on bringing its breakthrough FR-JET® technology and equipment portfolio to the market. The company is now entering a pivotal phase, transitioning from development to commercialization. In the coming months, LEON aims to establish key partnerships, expand manufacturing capabilities, and position itself as a leading enabler of high quality GMP nanoparticle manufacturing.
Dr. Hofmann brings 30 years
of experience in medicine, medical research, corporate strategy, financing, and
operational management within the pharmaceutical and medical technology
industries. He began his career at Dana-Farber Cancer Institute and Harvard
Medical School, contributing to early gene therapy systems. He later held
senior positions at Novartis and executive roles at Fresenius Group, covering
M&A, venture capital, and innovation management. As an entrepreneur, he has
founded companies and supports nonprofit institutions. Dr. Hofmann holds a
medical doctorate from the University of Heidelberg and an executive management
degree from Harvard Business School.
“I am thrilled to be
appointed CEO and to work with the outstanding team at LEON,” Hofmann said. “LEON
brings market-ready systems for the manufacturing of the most advanced lipid-
and polymer-based nanoparticles, as well as nanoprecipitation – used in the
pharma and biotech sectors and other high-tech fields where process quality and
control are essential. I am confident that LEON’s game changing systems will
transform these fields in quality, cost, and convenience in the near future.”
Dr. Hubert Birner, Chairman of the
LEON Supervisory Board, said: “We
are excited to appoint Dr. Hofmann as the new CEO of LEON. Dr. Hofmann brings key skills and
global experience to take LEON to the next level of development. This includes
the creation of partnerships and strategic options for the company, as well as
the commercialization of our exciting product range. We are confident that our
fully developed technology will serve pharmaceutical and other manufacturers
around the world to reach new levels of efficiency in development of their LNP-
or PNP-based projects and bring to market superior products based on our
platforms.”
Based in Munich, leon-nanodrugs GmbH is a Pharmatech
company specializing in the development of equipment for the encapsulation of
genetic material and other pharmaceutical active substances into nanocarriers,
such as lipid nanoparticles (LNPs). The company leverages its proprietary
FR-JET® technology to build innovative solutions. Its equipment portfolio
includes NANOscreen® for formulation screening (currently in development), NANOlab®
for process development as well as NANOme® and NANOus® for GMP manufacture.
These systems enable faster route to clinical batches and are suitable for both
individualized scales and commercial production. LEON’s platform aims to
empower pharmaceutical companies, small biotech, research institutes, and
CDMOs, to capitalize on advancements in advanced therapies. For further
information, please visit https://leon-nanodrugs.com/ and follow us on LinkedIn.
CONTACT: MEDIA INQUIRIES: leon-nanodrugs GmbH Maja Tinko-Kuhar, Marketing Director Phone: +49-89-41424889-98 MC Services AG Katja Arnold / Eva Bauer Phone: +49-89-210228-0
Dr.
Wolfgang Hofmann, CEO leon-nanodrugs GmbH. © LEON
For a high-res picture please contact
leon-nanodrugs@mc-services.eu.
